Synthetic studies on stevastelins. 2. Synthesis of lipidic- and peptidic-modified analogues

Journal of Organic Chemistry

Volumn 70, Issue 20, 2005, Pages 7858-7865

  Sarabia, Francisco ^a   Chammaa, Samy ^a   García Castro, Miguel ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CONFORMATIONS; SUBSTITUTION REACTIONS; SYNTHESIS (CHEMICAL);

ANALOGUES; CONFORMATIONAL FLEXIBILITY; LIPIDIC CHAIN; STEVASTELINS;

LIPIDS;

ALANINE; AMINO ACID; CYCLODEPSIPEPTIDE; GLYCINE; LIPID; NATURAL PRODUCT; SERINE; STEARIC ACID; STEVASTELIN; THREONINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; REACTION ANALYSIS; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS;

ALKYLATION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; DEPSIPEPTIDES; FUNGAL PROTEINS; INDICATORS AND REAGENTS; PEPTIDES; PEPTIDES, CYCLIC; STEARIC ACIDS;

EID: 25444441846     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo050628y     Document Type: Article

References (38)

1. See the preceding article on this issue: Sarabia, F.; Chammaa, S. J. Org. Chem. 2005, 70, 7846-7857.
2. For isolation of stevastelins, see: (a) Morino, T.; Masuda, A.; Yamada, M.; Nishimoto, M.; Nishikiori, T.; Saito, S.; Shimada, N. J. Antibiot. 1994, 47, 1341-1343.
3. For structural determination, see: (b) Morino, T.; Shimada, K.-I.; Masuda, A.; Nishimoto, M.; Saito, S. J. Antibiot. 1996, 49, 1049-1051.
4. For biological properties, see: (c) Morino, T.; Shimada, K.-I.; Masuda, A.; Noriyuki, Y.; Nishimoto, M.; Nishikiori, T.; Saito, S. J. Antibiot. 1996, 49, 564-568.
5. (d) Shimada, K.-I.; Morino, T.; Masuda, A.; Sato, M.; Kitagawa, M.; Saito, S. J. Antibiot. 1996, 49, 569-574.
6. For synthetic approaches of [15]-membered stevastelins, see: (a) Chakraborty, T. K.; Ghosh, S.; Dutta, S. Tetrahedron Lett. 2001, 42, 5085-5088.
7. (b) Sarabia, F.; Chammaa, S.; Sánchez-Ruiz, A.; López-Herrera, F. J. Tetrahedron Lett. 2003, 44, 7671-7675.
8. For total synthesis of stevastelin B, see: (a) Kohyama, N.; Yamamoto, Y. Synlett 2001, 694-696.
9. (b) Kurosawa, K.; Nagase, T.; Chida, N. Chem. Commun. 2002, 1280-1281.
10. For synthetic approaches of [13]-membered stevastelins, see; (a) Sarabia, F.; Chammaa, S.; López-Herrera, F. J. Tetrahedron Lett. 2002, 43, 2961-2965.
11. For total synthesis of stevastelin B3, see; (b) Kurosawa, K.; Matsuura, K.; Chida, N. Tetrahedron Lett. 2005, 46, 389-392.
12. (c) Chakraborty, T. K.; Ghosh, S.; Laxman, P.; Dutta, S.; Samanta, R. Tetrahedron Lett. 2005, 46, 5447-5450.
13. Hamaguchi, T.; Masuda, A.; Morino, T.; Osada, H. Chem. Biol. 1997, 4, 279-286.
14. Ma, P.; Martin, V. S.; Masamune, S.; Sharpless, K. B.; Viti, S. M. J. Org. Chem. 1982, 47, 1378-1380.
15. Nicolaou, K. C.; Oshima, T.; Murphy, F.; Barluenga, S.; Xu, J.; Winssinger, N. Chem. Commun. 1999, 809-810.
16. Rajashekhar, B.; Kaiser, E. T. J. Org. Chem. 1986, 51, 1625-1627.
17. Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. Bull. Chem. Soc. Jpn. 1979, 52, 1989-1993.
18. Hansen, T. M.; Florence, G. J.; Lugo-Mas, P.; Chen, J.; Abrams, J. N.; Forsyth, C. J. Tetrahedron Lett. 2003, 44, 57-59.
19. (a) Hale, K. J.; Bhatia, G. S.; Frigerio, M. In The Chemical Synthesis of Natural Products; Hale, K. J., Ed.; Sheffield Academic Press: Sheffield, 2000; pp 349-415.
20. (b) Sarabia, F.; Chammaa, S.; Sánchez-Ruiz, A.; Martín-Ortiz, L.; López-Herrera, F. J. Curr. Med. Chem. 2004, 11, 1309-1332.
21. (a) Yamada, S.; Kasai, Y.; Shioiri, T. Tetrahedron Lett. 1973, 1595-1598.
22. (b) Takuma, S.; Hamada, Y.; Shioiri, T. Chem. Pharm. Bull. 1982, 30, 3147-3153.
23. The overall yield of the total synthesis for all new stevastelin analogues is referred to the starting oxazolidinone described in the preceding article, according to Evans methodology: (a) Evans, D. A. Aldrichimica Acta 1982, 15, 318-327.
24. (b) Evans, D. A.; Bartroli, J.; Shih, T. L. J. Am. Chem. Soc. 1981, 103, 2127-2129.
25. (c) Evans, D. A.; Ennis, M. D.; Mathre, D. J. J. Am. Chem. Soc. 1982, 104, 1737-1739.
26. (d) Evans, D. A.; Mathre, D. J.; Scott, W. L. J. Org. Chem. 1985, 50, 1830-1835.
27. (e) Evans, D. A.; Scott, J. M.; Ennis, M. D. J. Org. Chem. 1993, 58, 471-485.
28. 4/NMO.
29. Uccello-Barretta, G.; Luliano, A.; Menicagli, R.; Peluso, P.; Pieroni, E.; Salvadori, P. Chirality 1997, 9, 113-121.
30. Gao, X.-M.; Ye, Y.-H.; Bernd, M.; Kutscher, B. J. Pept. Sci. 2002, 8, 418-430.
31. (a) Boden, E. P.; Keck, G. E. J. Org. Chem. 1985, 50, 2394-2395.
32. (b) Kiho, T.; Nakayama, M.; Kogen, H. Tetrahedron 2003, 59, 1685-1697.
33. Sajiki, H.; Hattori, K.; Hirota, K. J. Org. Chem. 1998, 63, 7990-7992.
34. Glycine residues contained in linear peptidic chains are known to enhance cyclization processes, see: (a) Kessler, H.; Hass, B. Int. J. Pept. Protein Res. 1993, 39, 36.
35. Despite this, we found in the literature examples of glycine-containing peptides which did not cyclize via a macrolactamization reaction. See: (b) Jeremic, T.; Linden, A.; Heimgartner, H. Helv. Chim. Acta 2004, 87, 3056-3079.
36. (a) Ziegler, F. E.; Kneisley, A.; Thottathil, J. K.; Wester, R. T. J. Am. Chem. Soc. 1988, 110, 5434-5442.
37. (b) Horita, K.; Oikawa, Y.; Yonemitsu, O. Chem. Pharm. Bull. 1989, 37, 1698-1704.
38. Bialy, L.; Waldmann, H. Angew. Chem., Int. Ed. 2005, 44, 3814-3839.